19 December 2018
  • Càncer
  • Medicina Regenerativa
  • Neurociències
  • Medicina Translacional

¡idiBELL Christmas and happy 2019!

Christmas card from Zoe López, a student of Institut Bellvitge

13 December 2018
  • Medicina Translacional

IDIBELL and Bellvitge University Hospital develop a new treatment to fight against hospital infections

Bacteria resistance to antibiotics is one of the most pressing issues in public health worldwide. The continuous growth of infections caused by these microbes can cause more than 10 million deaths per year in the year 2050, as it happened in the preantibiotic era.

12 December 2018
  • Neurociències

An intellectually active lifestyle protects against neurodegeneration in people with Huntington's disease

Researchers from the Cognition and Brain Plasticity research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona (UB), in collaboration with several hospitals, have discovered that an intellectually active lifestyle confers protection against neurodegene

05 December 2018

Álvaro Aytés i Katia Ruggero

  • Càncer

Researchers identify a new therapeutic target for metastatic and resistant prostate cancers

A new combined therapy to fight the most aggressive and resistant prostate cancers. This is one of the conclusions reached by Prostate Cancer researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Álvaro Aytés.

28 November 2018
  • Càncer

Ruth Rodríguez Barrueco, L'Oréal-UNESCO Research Award "For Women in Science"

IDIBELL - University of Barcelona researcher Ruth Rodríguez Barrueco has been awarded one of the five L'Oréal-UNESCO Research Awards "For Women in Science" in its 2018-19 call. The award, worth € 15,000, will support and promote the project carried out by Dr.